• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Kenny flies co helicopter to work?

Let's be honest. You can teach a scientist or doctor financial concepts, but that is not true the other way around. That is why you have a CFO. In Merck's case, all the sound scientists started leaving in the 1990's and just kept going. The company has trust issues with the FDA, with the medical community and Wall Street. Nothing but a total house cleaning is going to help this company. Personally, it's sad to watch such a once great company fail.